Matthew Barcus
Stock Analyst at Chardan Capital
(2.93)
# 1,615
Out of 4,711 analysts
23
Total ratings
21.74%
Success rate
20.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $14 → $12 | $2.28 | +426.32% | 2 | Nov 8, 2024 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $16.98 | +59.01% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $1.28 | +446.88% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $25.86 | +23.74% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $3.42 | +6,332.75% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.69 | +234.57% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $10.97 | -27.07% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.21 | +1,348.58% | 3 | Nov 17, 2022 |
Zura Bio
Nov 8, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $2.28
Upside: +426.32%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $16.98
Upside: +59.01%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $1.28
Upside: +446.88%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $25.86
Upside: +23.74%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $3.42
Upside: +6,332.75%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.69
Upside: +234.57%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $10.97
Upside: -27.07%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.21
Upside: +1,348.58%